We previously reported that all-trans retinoic acid (ATRA) and granulocyte-macrophage colony-stimulating factor (GM ± CSF) synergistically induced granulocytic dierentiation in human myeloblastic leukemia ML-1 cells. The combination of these agents also suppressed DNA-synthesis. In the present study, we investigated the suppression of cyclin dependent kinase (CDK) activities resulting in G1 arrest in dierentiated ML-1 cells. We show that treatment of ML-1 cells with ATRA plus GM-CSF results in G1 arrest and suppression of CDK activities. Protein levels of the G1 CDKs were essentially unchanged during this time. However, we observed an increase in CDK2-bound p27 and CDK4-bound p18, and a decrease in CDK6-bound cyclin D3. These results suggest that complex regulation of CDKs play a key role in G1 arrest of ML-1 after treatment with ATRA and GM ± CSF. We also showed that an increase in CDK2-bound p27 and CDK4-bound p18 are caused by treatment with ATRA and a decrease in CDK6-bound cyclin D3 is induced synergistically by treatment with both reagents. Furthermore, we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in p27 binding to CDK2 is due to a novel mechanism. Oncogene (2000) 19, 4640 ± 4646.
Introduction
In mammalian cells, signals that induce or facilitate dierentiation often do so through regulation of the cell cycle. Cell proliferation and dierentiation are tightly linked. Terminal dierentiation is associated with an irreversible loss of proliferative potential. However, little is known about how cell cycle arrest is initiated during dierentiation.
The cell cycle is regulated by cyclin dependent kinases (CDKs) that are regulated in turn by phosphorylation and binding to their regulatory subunits, cyclins. Each cyclin/CDK combination appears to regulate speci®c events in the cell cycle (Pardee, 1989; Norbury and Nurse, 1992) . Binding of CDK4 and CDK6 to D-type cyclins appears to be important for regulation of the transit through G1 (Matsushime et al., 1992) . The G1/S transition appears to be regulated primarily by CDK2 (Fang and Newport, 1991) . CDK2 binds primarily to cyclin E and A (Rosenblatt et al., 1992; Ko et al., 1992) . These CDKs regulate G1/S transition through phosphorylation of retinoblastoma tumor suppressor (Rb) gene product. A group of small proteins called CDK inhibitors (CKIs) that interact with and inhibit the activity of cyclin/CDK complexes act as negative regulators of growth by causing cells to arrest in G1 and withdraw from the cell cycle (Sherr and Roberts, 1995) . The CKIs are grouped into two classes. Members of Cip/Kip family, include p21 (Xiong et al., 1993; El-Diery et al., 1993; Harper et al., 1993; Noda et al., 1994) , p27 (Toyoshima and Hunter, 1994; Polyak et al., 1994a) and p57 (Lee et al., 1995) that bind to and inhibit cyclin/CDKs complexes. However, in recent study, Cheng et al. (1999) have reported that p21 and p27 are essential for formation of active CDK4/6-containing complexes. It has been established that p21 and p27 are positive and negative regulators of G1-phase progression . A second group, the Ink4 family is composed of p15, p16, p18 and p19 (Serrano et al., 1993; Guan et al., 1994; Hirai et al., 1995; Chan et al., 1995) members. These INK inhibitors induce G1 arrest by associating exclusively with CDK4 and CDK6 thus preventing their association with cyclin D. Evidence is accumulating that CKIs are targets of extracellular and intracellular signals that regulate cell growth and dierentiation. For example, p21 is induced by p53 in response to DNA damage resulting in CDK inhibition and G1 growth arrest (Dulic et al., 1994) . Transforming growth factor-b induces G1 arrest primarily by induction of p15 and by redistribution of p27 from CDK4 to CDK2 (Polyak et al., 1994b; Reynisdottir et al., 1995) . MyoD increases p21 expression, which is associated with muscle cell dierentiation (Halevy et al., 1995) . In hematopoietic cells, ectopic overexpression of CKIs such as p21 and p27 leads directly to terminal dierentiation (Liu et al., 1996) .
ML-1 cells which were derived from a patient with acute myeloblastic leukemia, are at an earlier stage of dierentiation than HL-60 cells and can be dierentiated easily into the macrophage but not the granulocytic pathway by various inducers such as tumor necrosis factor (Takeda et al., 1986) , interferon-g (Takei et al., 1984) and 12-O-tetradecanoylphorbol-13-acetate (TPA) (Takeda et al., 1982; Saito et al., 1999) . Retinoids generally do not promote granulocytic maturation in acute myeloid leukemia (AML) subtypes with the exception of acute promyelocytic leukemia (APL). However, we previously induced dierentiation in the granulocyte pathway in ML-1 cells by treatment with all-trans retinoic acid (ATRA) in combination with granulocyte-macrophage colony-stimulating factor (GM ± CSF) (Oka and Takeda, 1997) . Furthermore, we detected change to the hypophosphorylated form of pRB during the induced dierentiation . Based on these ®ndings, we hypothesized that CDK activities are inhibited and subsequent arrest of cells in G1 occurs in dierentiated ML-1 cells after treatment with ATRA combined with GM ± CSF. Therefore, we attempted to study cell cycle and CDK regulation during dierentiation.
We report that treatment of ML-1 cells with ATRA plus GM ± CSF results in G1 arrest and suppression of CDK activities. Moreover, based on our analysis of the mechanism for the suppression of CDK activity, we propose that suppression of CDK activities is achieved by complex regulation of CDKs.
Results
G1 arrest in ML-1 cells treated with ATRA plus GM-CSF ML-1 cells were induced to dierentiate toward the granulocytic pathway by combined treatment with ATRA and GM ± CSF. To analyse cell cycle alterations during this dierentiation process, we examined cellular DNA content by propidium iodide staining and¯ow cytometric analysis at 1, 2, 4, and 7 days after treatment with ATRA plus GM-CSF (Figure 1 ). Untreated cells showed the expected pattern for continuously growing cells. On the other hand, cells treated with both reagents showed a gradual accumulation of G1-arrested cells after treatment for 2 days. After 7 days, approximately 70% of cells were arrested in G1 phase and a minor population of the cells appeared to be proceeding toward apoptosis.
Suppression of CDK activities in ML-1 cells treated with ATRA plus GM-CSF Because regulation of the G1 phase of the cell cycle has been shown to involve the G1 CDKs (CDK2, CDK4 and CDK6), ATRA and GM ± CSF may limit the kinase activities of these CDKs, which then prevents the cells from completing G1 phase. To investigate the mechanisms of G1 arrest during dierentiation of ML-1 cells, we examined activities of CDKs in ML-1 cells treated with ATRA plus GM ± CSF. CDK2, CDK4 and CDK6 were immunoprecipitated from cellular lysates with an excess of antibody and assayed for kinase activity. The activities of CDK2 and CDK4 were stimulated slightly at 1 day after treatment and were suppressed at 3 and 6 days when cells had accumulated in the G1 phase of the cell cycle ( Figure  2 ). Quantitative analysis of the band showed 80 and 10% reductions in CDK2 kinase activity and 64 and 15% reductions in CDK4 kinase activity at 3 and 6 days, respectively, after treatment with both reagents. In CDK6 kinase activity, we detected 65, 26 and 6% reductions at 1, 3 and 6 days, respectively, after treatment. To investigate the mechanism behind the decrease in CDK kinase activity, we attempted to examine the expression of CDKs in ML-1 cells treated with ATRA plus GM ± CSF. No changes in the levels of CDK2, CDK4 or CDK6 proteins were detected during dierentiation ( Figure 3 ). This result is consistent with our previous ®ndings . Since CDK activities are regulated by binding of cyclins and CKIs, a decrease in CDK kinase activity may be due to changes in CDK complexes. To investigate the status of CDK complexes during granulocytic dierentiation of ML-1 cells, we performed a two-step experiment that consisted of immunoprecipitation with anti-CDK antibody followed by Western blot analysis with anticyclins and anti-CKIs (Figure 4 ). The amount of p27 protein associated with CDK2 increased 3 ± 6 days after treatment with ATRA plus GM ± CSF. We also detected an increase in p18 binding to CDK4 after treatment for 3 days. In contrast, binding of CKIs to CDK6 did not change in dierentiated ML-1 cells, but we found a decrease in cyclin D3 binding to CDK6 after treatment for 3 days. Expression of cyclin D2, p16, and p19 was detected in ML-1 cells, but binding to CDK was not detected (data not shown). Expression of cyclin D1, p15 and p21 was not detected in dierentiation-induced or in non-induced cells (data not shown). These observations suggest that complex regulation of CDKs suppress the kinase activities of CDKs during granulocytic dierentiation of ML-1 cells. We next examined the expression of p27, p18 and cyclin D3 in ML-1 cells treated with both reagents for 1, 3, and 6 days ( Figure 5a ). We found that cyclin D3 decreased and that p18 increased after treatment for 3 days. These results suggest that decreased cyclin D3 binding to CDK6 and increased p18 binding to CDK4 are due to changes in the expression of each protein. In contrast, expression of p27 did not change during induced dierentiation. Furthermore, the level of p27 binding to CDK4 and CDK6 also did not change during dierentiation of ML-1 cells (Figure 4) . To con®rm the status of p27 binding to CDKs, we performed immunoprecipitation with anti-p27 antibody and Western blot analysis with anti-CDKs. As is shown in Figure 5b , we detected an increase in p27 binding to CDK2 without changes in binding to other CDKs. From these results, it is clear that increased binding of p27 to CDK2 is not due to altered protein expression or redistribution from other CDKs.
Complex regulation of CDKs in ML-1 cells treated with ATRA or GM ± CSF alone
To investigate the signal of complex regulation of CDKs, we examined complex regulation of CDKs and the expression level of p27, p18 and cyclin D3 in ML-1 cells treated with ATRA or GM ± CSF alone. As shown in Figure 6 , we detected that the signal of ATRA caused the increase of p27 binding to CDK2 and p18 binding to CDK4. In addition, the increase of p18 expression also was caused by treatment with ATRA. In contrast, Cyclin D3 binding to CDK6 was decreased by treatment with ATRA, but degree of the decrease was weaker than that of ML-1 cells treated with ATRA and GM ± CSF. The expression of Cyclin D3 was minimally altered by treatment with ATRA alone. These results suggest that cyclin D3 binding to CDK6 and the expression of cyclin D3 are decreased synergistically by treatment with ATRA and GM ± CSF. 
Discussion
Terminal dierentiation that occurs spontaneously or as a consequence of treatment with speci®c induction agents is correlated with an irreversible loss of proliferative potential. In this study, we found that G1 cell cycle arrest and decreased CDK activities accompany granulocytic dierentiation in human myeloblastic ML-1 cells treated with ATRA plus GM ± CSF. To understand the mechanism of suppression of CDK activity, we investigated the complex regulation of CDKs during dierentiation. We present evidence demonstrating that suppression of CDK activities is due to changes in binding of p18, p27, and cyclin D3 to CDKs. p18 expression levels have been shown to increase during the granulocytic dierentiation of HL60 cells by DMSO or the terminal dierentiation of B cells to plasma cells (Schwaller et al., 1997; Morse et al., 1997) . Franklin and Xiong (1996) reported that induction of p18 and subsequent complex formation with CDK4 and CDK6 play a critical role in cell cycle arrest associated with mature muscle formation. Several laboratories have shown that induction of p27 is associated with cell arrest and the terminal macrophage-like dierentiation caused by exposure to phorbolester or 1,25-dihydroxyvitamin D 3 (Asiedu et al., 1997; Wang et al., 1996) . These observations suggest that induction of CKIs and sequential inhibition of CDKs play an important role during dierentiation. When total p18 was analysed by Western blotting, we detected a slight increase in p18 protein levels after 3 days of treatment with ATRA plus GM ± CSF. In contrast, binding of p18 to CDK4 increased markedly after 3 days of treatment. These results suggest that induction of p18 stimulates binding of p18 to CDK4. It may be that there are also other mechanisms for stimulation of p18 binding activity. We detected a remarkable increase in binding of p27 to CDK2 in dierentiated ML-1 cells, which showed minimal increases in p27 expression. ReynisdoÂ ttir et al. 77 M ATRA and 0.1 ng/ml GM ± CSF for the times indicated. Protein lysates were prepared, and Western blots were performed as described in Materials and methods. (b) Analysis of p27 complexes in ML-1 cells treated with ATRA plus GM-CSF. Cell lysates were prepared from ML-1 cells treated with 10 77 M ATRA and 0.1 ng/ml GM ± CSF for the times indicated. Cell lysates were immunoprecipitated with antibodies to p27. The immunoprecipitate was subjected to SDS ± PAGE and immunoblotted with antibodies to p27 and CDKs as indicated Figure 4 Analysis of CDK complexes in ML-1 cells treated with ATRA plus GM ± CSF. Cell lysates were prepared from ML-1 cells treated with 10 77 M ATRA and 0.1 ng/ml GM ± CSF for the times indicated. Cell lysates were immunoprecipitated with antibodies to CDK2, CDK4 and CDK6 as indicated. The immunoprecipitates were subjected to SDS ± PAGE and immunoblotted with antibodies to CDKs, cyclins and CKIs as indicated Oncogene Complex regulation of CDKs in differentiated ML-1 cell T Shimizu et al (1995) reported that the induction of p15 causes redistribution of p27 from CDK4 to CDK2. Lovastatin-mediated G1 arrest occurs through redistribution of both p21 and p27 from CDK4 to CDK2 without increased p21 and p27 protein expression (Rao et al., 1998) . We were led to hypothesize that the increased binding of p27 to CDK2 in dierentiated ML-1 cells was due to redistribution of p27 and increased binding of p18 to CDK4. However, it is not likely that the increased binding of p27 to CDK2 is due to redistribution of p27 from CDK4, because we did not detect decreased binding of p27 to CDK4 or CDK6 in dierentiated ML-1 cells. The increased binding of p27 to CDK2 may be due to a novel mechanism regulating CKI binding to CDK.
Several groups have studied p27 regulation. MuÈ ller et al. (1997) proposed that phosphorylation of p27 facilitates its Myc-induced release from cyclin E-CDK2 complexes. Since regulation of protein complexes by phosphorylation is widely accepted, phosphorylation of p27 may be a mechanism for regulation of p27 binding to CDKs. The recently proposed mechanism for p27 regulation involves subcellular compartmentalization. p27 appears to interact with its targets in the cell nucleus, and mislocalization of p27 in the cytoplasm might inactivate p27 by sequestering it away from relevant cellular targets (ReynisdoÂ ttir and MassagueÂ , 1997) . In fact, cytoplasmic mislocalization of p27 has been reported in human tumors and cell lines (Orend et al., 1998) . A recent study of Barrett's-associated esophageal adenocarcinoma found subcellular cytoplasmic localization of p27 in more than half of esophageal adenocarcinomas (Singh et al., 1998) . We also performed a preliminary examination about change of the localization of p27 protein during the granulocytic dierentiation of ML-1 cells by Western blotting using cytosol and nuclear extracts. However, we did not detect change of the localization of p27 protein during the dierentiation. It is likely that the increase of p27 bind to CDK2 is not associated with localization of p27 and is due to the other mechanism.
More recent work has revealed that although p21 and p27 proteins are potent inhibitors of cyclin E-CDK2 and cyclin A-CDK2, they act as positive regulators of cyclin D-CDK (Cheng et al., 1999, Sherr and . Our results showed that the amount of p27 and cyclin D3 binding to CDK4 did not change during the dierentiation of ML-1 cells. However, the activity of CDK4 nearly disappeared at 6 days after treatment. Regarding the mechanism of inactivation of the CDK4-cyclin D3-p27 complex, one possibility is to assume that regulation of phosphorylation of CDK4 by cdc25A or CAK, another possibility is formation of complex containing higher ratio of p27 to cyclin D3-CDK4 or another subunit for regulation.
We observed decreased binding of cyclin D3 to CDK6 and decreased expression of cyclin D3 protein 3 ± 6 days after treatment of ML-1 cells with ATRA plus GM ± CSF. This suggests that the decrease in binding of cyclin D3 to CDK6 is associated with suppression of CDK6 activity in dierentiated ML-1 cells. However, there may be other mechanisms for suppression of CDK6 activity, because suppression of CDK6 activity was observed by 1 day after treatment. We reported previously that expression of cdc25A rapidly decreases 1 day after treatment . Decreased expression of cdc25A may be associated with suppression of CDK6 activity at an early stage of dierentiation in ML-1 cells.
In this study, we used ATRA and GM ± CSF to induce dierentiation. Some groups reported that ATRA regulate various cell cycle related genes and suppress cell growth (Matsuo and Thiele, 1998; Sueoka et al., 1999; Naderi and Blomho, 1999) . We also revealed that ATRA caused the increase of p27 binding to CDK2 and p18 binding to CDK4. Matsuo and Thiele (1998) also have reported an increase in G1 cyclin/CDK bound p27 by retinoic acid in neuroblastoma cell lines. However, their data have suggested the increase of p27 binding is due to change in expression level of p27. This observation was not consistent with the results of our study. In addition to this, it has not been reported that ATRA induce the expression of p18 and the binding of p18 to CDK4. Analysis of these mechanisms may contribute some novel information about action of cell growth suppression by ATRA. In contrast, the decrease of cyclin D3 expression and cyclin D3 binding to CDK6 was stimulated synergistically by ATRA combined with GM ± CSF. Langenfeld et al. (1997) reported that retinoic acid directly causes a decline in cyclin D1 protein expression through induction of proteolysis. Another group showed that retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced dierentiation of tumor cells (Spinella et al., 1999) . It may be that repression of cyclin D3 protein during dierentiation of ML-1 cells is caused by a similar mechanism, since we could not detect any alteration of 77 M ATRA or 0.1 ng/ml GM ± CSF for the times indicated. Cell lysates were immunoprecipitated with antibodies to CDK2, CDK4 and CDK6 as indicated. The immunoprecipitates were subjected to SDS ± PAGE and immunoblotted with antibodies to p27, p18 or cyclin D3. (b) Expression levels of p18, p27 and cyclin D3 in ML-1 cells treated with ATRA or GM ± CSF alone. Cultures were treated with 10 77 M ATRA or 0.1 ng/ml GM ± CSF for the times indicated. Protein lysates were prepared and Western blots were performed as described in Materials and methods
Complex regulation of CDKs in differentiated ML-1 cell T Shimizu et al cyclin D3 mRNA expression during induced dierentiation of ML-1 cells . The decrease of cyclin D protein by ATRA may be stimulated by combined treatment with GM ± CSF. The identi®cation of CKIs and cyclins as candidate genes that couple dierentiation signals to growth arrest is appealing on several levels. Our results suggest that regulation of p18, p27 and cyclin D3 play an important role in growth arrest during dierentiation of ML-1 cells. Clari®cation of the mechanism of regulation may reveal novel targets for dierentiation therapy in various cancers.
Materials and methods

Cell culture and treatment
Cells of the human myeloblastic leukemia cell line, ML-1, were maintained as suspension cultures in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Filtron Pty. Ltd., Victoria, Australia). Incubation was carried out at 378C in a humidi®ed 5% CO 2 incubator. ATRA (Sigma Chemical Co., St. Louis, MO, USA) was added to the culture medium at the ®nal concentration of 10 77 M, and rHuGM-CSF (Sandz, Wien, Austria) was added to the culture medium at the ®nal concentration of 0.1 ng/ml.
Flow cytometry
ML-1 cells were treated with 10
77 ATRA and 0.1 ng/ml GM ± CSF for 1, 2, 4 and 7 days. The cells were harvested and ®xed with 70% EtOH. Fixed cells (at least 1610 4 cells) were treated RNase and stained with propidium iodide, and DNA contents were analysed using a FACS Caliber¯ow cytometer and Cell Quest software (Becton Dickinson, San JoseÂ , CA, USA)
CDK kinase assay
Kinase assay was performed according to the method described by Matsusime et al. (1994) . Cell lysates were prepared by suspension of 1610 7 cells/ml in IP1 buer [50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5), 150 mM NaCl, 1 mM EDTA, 2.5 mM ethylene glycol-bis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.1% Tween-20] containing 10% glycerol, 0.1 mM phenylmethylsulfonyl uoride (PMSF), 10 mg/ml leupeptin, 20 U/ml aprotinin, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate, then sonication and centrifugation. Cell lysates were incubated for 4 h at 48C with protein A/GSepharose beads precoated with saturating amounts of the following antibodies: polyclonal anti-Cdk2 (M2), Cdk4 (H-22) and Cdk6 (C-21) from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Immunoprecipitated proteins on beads were washed four times with 1 ml of IP1 buer and twice with 50 mM HEPES containing 1 mM DTT. The beads were suspended in 30 m1 of kinase buer [50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM DTT] containing substrate [either 0.2 mg of soluble glutathione S-transferasepRB fusion protein (Santa Cruz Biotechnology, Inc.), or 1 mg of histone H1 (Boehringer Mannheim, Indianapolis, IN, USA)] and 2.5 mM EGTA, 10 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM NaF, 20 mM ATP and 10 mCi of [g-32 P]ATP (NEN Dupont, Boston, MA, USA; 6000 Ci/mmol). After incubation for 30 min at 308C, the samples were boiled in sample buer and separated by SDS ± PAGE. Phosphorylated proteins were visualized by autoradiography.
Isolation of cell extracts
For whole cell extracts, cell lysates were prepared by suspension of 1610 7 cells in lysis buer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1% deoxycholate, 0.05% SDS, 0.1 mM PMSF and 10 mg/ml of aprotinin] and repetition of freezing and melting. Whole cell extracts were centrifuged to remove insoluble cell debris.
Immunoprecipitations
Cell lysates were prepared by suspension of 1610 7 cell/ml in IP2 buer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM DTT] containing 1 mM PMSF, 10 mg/ml leupeptin, 20 U/ml aprotinin, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate and centrifugation. Cell lysates were incubated for 4 h at 48C with protein A/G-Sepharose beads precoated with saturating amounts of the following antibodies: polyclonal anti-Cdk2 (M2), Cdk4 (H-22), Cdk6 (C-21) and p27 (C-19) from Santa Cruz Biotechnology, Inc. Immunoprecipitated proteins on beads were washed four times with 1 ml of IP2 buer, then subjected to Western blot analysis.
Western blot analysis
The denatured cell extracts or immunoprecipitates were analysed by SDS ± polyacrylamide gel electrophoresis. The proteins were transferred to a PVDF membrane. The blots were blocked at 48C using 5% nonfat milk overnight in PBS-T (10 mM PBS ± 0.05% Tween 20) and incubated for 2 h at room temperature with the following primary antibodies: monoclonal anti-cyclin A (BF683) and cyclin E (HE12), polyclonal anti-Cdk2 (M2), Cdk6 (C-21), cyclin D2 (C-17), p16 (C-20) and p19 (M-167) from Santa Cruz Biotechnology, Inc.; monoclonalanti-cdk4 (Clone 97), cyclin D3 (Clone 1) and p27 (Clone 57) from Transduction Laboratories (Lexington, KY, USA); polyclonal anti-p18 from Upstate Biotechnology (Lake Placid, NY, USA). The blots were then washed three times and incubated for 1 h with HRPconjugated secondary antibodies. Proteins were visualized using the ECL detection system (Amersham Pharmacia Biotech, Uppsala, Sweden).
